Gyre Therapeutics, formerly known as Catalyst Biosciences, completed a business combination with GNI USA, GNI Group, GNI HK, Shanghai Genomics, and CPI, resulting in a name change and a reverse stock split; Gyre is now a biopharmaceutical company focused on organ fibrosis treatment.